Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 20,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood sample Clear all
Terminated Phase 2 Interventional

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
cetuximab, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 4 Interventional Results available

Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

NCT01582282
View directory record Official record
Conditions
Non-Insulin-dependent Diabetes Mellitus
Interventions
placebo, 3.4 g psyllium BID, 6.8g psyllium BID
Dietary Supplement
Lead sponsor
Procter and Gamble
Industry
Eligibility
36 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 1990
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

NCT01489059
View directory record Official record
Conditions
Melanoma
Interventions
BMS-982470 (recombinant interleukin-21), Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 18, 2026, 5:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

FoxBioNet: ECV (Extracellular Vesicle) 004

NCT04603326
View directory record Official record
Conditions
Parkinson Disease
Interventions
Lumbar Puncture
Procedure
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 18, 2026, 5:21 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines

NCT02563678
View directory record Official record
Conditions
Infection
Interventions
Hyperbaric Oxygen, Hyperbaric Air/Oxygen, Normobaric oxygen
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 18, 2026, 5:21 PM EDT
Recruiting Phase 1 Interventional

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06859008
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Sonrotoclax, Zanubrutinib
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Not applicable Interventional

Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease

NCT02112825
View directory record Official record
Conditions
Focus Chronic Kidney Disease With Hypertension
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mobile Health Platform

NCT02099513
View directory record Official record
Conditions
Obesity, Hypertension, Diabetes
Interventions
The Mobile Health Platform
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 18, 2026, 5:21 PM EDT
Completed No phase listed Observational

ImmuneSense™ COVID-19 Study

NCT04583982
View directory record Official record
Conditions
Coronavirus Disease (COVID-19), SARS-CoV-2 Infection
Interventions
T-Detect™ SARS-CoV-2 Assay
Other
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Not applicable Interventional Results available

Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response

NCT02807480
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Exposure-based therapy, Behavioral Activation therapy, Computer-based behavioral assessment, Surveys and Interviews, Magnetic resonance imaging (MRI), Electroencephalography (EEG)
Behavioral · Device
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Not applicable Interventional

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

NCT03618979
View directory record Official record
Conditions
Low Back Pain
Interventions
PPP treatment, PRP treatment, PRP and PL Combo treatment
Biological
Lead sponsor
Regenexx, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Broomfield, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Early Phase 1 Interventional

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

NCT03812562
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Yttrium Y 90 Glass Microspheres
Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Artificial Pancreas Control System in an Inpatient Setting

NCT01552603
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Artificial Pancreas Control Software
Device
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Blood Brain Flow and Exercise

NCT02653638
View directory record Official record
Conditions
Cerebrovascular Circulation
Interventions
Control, Indomethacin
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional

Vascular Sealant Study

NCT00618358
View directory record Official record
Conditions
Arteriovenous Access Grafts or Extra-anatomic and Infra-inguinal Grafts
Interventions
Vascular Sealant System, Gelfoam/Thrombin
Device · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Timeline
Started 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated No phase listed Observational

Genetic Mechanisms in Human Hypertension

NCT01456208
View directory record Official record
Conditions
Hypertension
Interventions
Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

NCT03459040
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD
Interventions
Alpha 1-Antitrypsin
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional Results available

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

NCT03973918
View directory record Official record
Conditions
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
Interventions
Encorafenib, Binimetinib, Research Bloods, Tumor Tissue
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 18, 2026, 5:21 PM EDT
Recruiting Early Phase 1 Interventional

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions
Encorafenib Pill, Binimetinib Pill, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

NCT01932060
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Oxytocin Infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

NCT00387959
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 18, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

NCT02200380
View directory record Official record
Conditions
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Non-Hodgkins Lymphoma (NHL), Hodgkins Disease (HD), Chronic Lymphocytic Leukemia (CLL)
Interventions
CDX-301, CDX-301 and plerixafor
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 18, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
BMS-986012 (anti-fucosyl-GM1), Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 18, 2026, 5:21 PM EDT